Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for use in adults…
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) AstraZeneca and Merck (NYSE: MRK),known as MSD outside…
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) and…
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor)…
Kate Eversteyn joins WHO as PRSEAH Coordinator for Europe Kate Eversteyn is a self-described “social worker by trade” with over 28 years of experience, with the last 13 years focused…
World Health Assembly recognizes WHO’s work on PRSEAH, calls for continued action Australia (on behalf of 63 Member States from across WHO’s regions), Botswana (on behalf of the 47 African…
WHO launches a single-source repository on drug dependence information The repository, from WHO’s Expert Committee on Drug Dependence (ECDD), is an important resource for health professionals, drug policy experts and policy-makers,…
Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial Positive high-level results from a planned interim analysis of the MATTERHORN…
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved…
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus AbbVie (NYSE: ABBV) today announced the…
Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical stage drug discovery company, announced that the U.S. Food…
U.S. FDA approves ABRYSVO™, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA)…